Albemarle has delivered a strong 63.4% share price gain over the past year, yet its valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to the stock trading at a sizeable discount, while market based multiples and a low overall value score suggest the shares are not a clear bargain.

• Over the last 12 months Albemarle is up 63.4%, which puts recent returns firmly ahead of the company’s three and five year share price record.
• Investor expectations for lithium demand and pricing can support the intrinsic value case, while any reversal in those expectations may weigh heavily on what investors are willing to pay for Albemarle’s future cash flows.
• The stock only passes 2 of 6 valuation checks on Simply Wall St’s broader framework, which leans more toward Albemarle looking expensive than clearly underpriced, even though the Discounted Cash Flow (DCF) estimate suggests it may be undervalued by about 46.8%.

The issue now is whether that mix of strong recent returns and conflicting valuation signals leaves Albemarle trading closer to opportunity or to optimism.

Is Albemarle a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Albemarle could be worth based on the cash it is expected to generate for shareholders. The model uses last twelve month free cash flow of about $619 million as a starting point and then assumes those cash flows grow over time rather than shrink, which implies a recovering or growing profile for the business.

On this basis, the DCF points to an intrinsic value of about $252 per share. That is roughly 46.8% above the current market price, so the stock appears undervalued on this method. Albemarle's strong Q2 2026 report, helped by higher lithium prices and demand, may support the cash flow outlook. However, the share price still sits below the level suggested by this model for its future cash flows.

On the DCF numbers alone, Albemarle stock appears undervalued relative to the cash flows implied in the model.

Our Discounted Cash Flow (DCF) analysis suggests Albemarle is undervalued by 46.8%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Has Albemarle Run Too Far on Sales?

The P/S multiple suits Albemarle because revenue is a key reference point for a company tied to commodity linked volumes and pricing. Albemarle currently trades on a P/S of 2.7x, which is above both the Chemicals industry average of 1.1x and a peer group average of 2.6x. That puts the stock at a premium to the sector as well as close peers on a simple sales basis.

The Simply Wall St fair P/S ratio for Albemarle is 1.9x, which reflects what the P/S might look like once factors such as its size, margins and risk profile are taken into account. The current 2.7x level is therefore higher than this tailored benchmark and points to Albemarle stock looking overvalued on sales alone rather than cheap against either the industry or that fair ratio.

On the P/S multiple, Albemarle shares look overvalued compared with both industry norms and the fair ratio estimate.

The Albemarle Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Albemarle's valuation puzzle leaves off by spelling out the growth, margin and earnings paths that would need to hold for the stock to be worth materially more or less than today's price on the Community page. Rather than relying on a single multiple or model output, each one lays out the assumptions behind its fair value so you can compare them with Albemarle's actual results over time.

The Albemarle community is split between a tight supply and policy support story and a tougher long term lithium and regulation risk story.

Bull case: 28% undervalued

"With ~50% of sales volumes locked under long-term agreements with major Western OEM and battery customers, Albemarle benefits from enhanced revenue stability and reduced cyclicality..."

Bear case: 8% overvalued

"Ongoing global lithium supply expansions, combined with visible overcapacity in Chinese conversion facilities and periods of market surplus, point to intensifying commoditization, eroded pricing power, and heightened cyclicality..."

Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!

The Bottom Line

Albemarle presents a split picture. The Discounted Cash Flow (DCF) intrinsic value estimate points to the stock trading at a discount to its projected cash flows, while market multiples still frame it as overvalued relative to peers and a tailored fair ratio. Broader valuation checks remain weak, so that intrinsic value signal sits against a cautious backdrop rather than clear value. The real hinge from here is whether Albemarle can sustain the cash flow profile implied in the DCF in the face of lithium price and demand risks, or whether the market view that current expectations are already full proves more accurate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.